Gastric Cancer Highlights Positive readout shared in February 2023 ESMO plenary showed significant improvement in mPFS and mOS in...

RCC Highlights Negative results from the Phase III IMmotion010, CheckMate-914 Part A, and PROSPER trials call into question the benefit...

Highlights Long-term follow-up analyses from Phase III SOLO-1 (olaparib maintenance treatment in 1L BRCAm ovarian cancer) and Phase III...

In this report, Axiom provides a review on pivotal and paradigm shifting data from the first half of 2022 and offers our perspective on...

Executive Summary IO360 underscored the importance of the starting cell type, as the overall consensus of the superior cell type was the...

In this report, Axiom provides overview of key advances in 2021, and offer our perspective on emerging trends and their implications...

Practice changing new data was presented at the ESMO Congress 2021. Take a look at the Axiom’s ESMO 2021 highlights.

ASCO 2021 - Thoughts from the Think Tank. In this ASCO recap, we share our analysis on major updates in solid tumors including thoughts...

Highlights Results from monarchE (abemaciclib + ET) confirm the benefit of abemaciclib in in high risk, HR+ BC Although FDA ODAC voted...

Any apprehension that COVID-19 would also disrupt the legacy of ASCO innovation, was ameliorated by a procession of breakthrough findings...

A global consortium of thousands of researchers published a groundbreaking oncology paper in Nature. They investigated the evolution of...

ESMO 2019 featured a staggering 2,200 abstracts including 92 late breaking abstracts, befitting its standing as one of the largest...

The meeting provided a spectrum of practice-changing studies, early-stage data for novel therapies, and advances in notable trends such...